KGF-2 Protects against Lung Ischemia-Reperfusion Injury by Inhibiting Inflammation-Induced Damage to Endothelial Barrier Function

Fangfang Xia; Zhousheng Jin; Jiaojiao Dong; Chaoxing Chen; Yaoyao Cai; Quanguang Wang; Hongfei Chen

doi:10.1155/2022/3055039

KGF-2 Protects against Lung Ischemia-Reperfusion Injury by Inhibiting Inflammation-Induced Damage to Endothelial Barrier Function

Evid Based Complement Alternat Med. 2022 May 11:2022:3055039. doi: 10.1155/2022/3055039. eCollection 2022.

Authors

Fangfang Xia¹, Zhousheng Jin¹, Jiaojiao Dong¹, Chaoxing Chen¹, Yaoyao Cai¹, Quanguang Wang¹, Hongfei Chen¹

Affiliation

¹ Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, China.

Abstract

Lung ischemia-reperfusion injury (LIRI), which has a mortality rate of approximately 50%, is a popular topic in critical care research. Keratinocyte growth factor-2 (KGF-2) is secreted by mesenchymal cells, and it is effective in promoting the proliferation, migration, and differentiation of various epithelial cells. To date, however, only a few reports on KGF-2-related regulators in LIRI have been published. In the current study, an LIRI rat model is constructed, and the upregulation of the fibroblast growth factor receptor 2 (FGFR2) is observed in the LIRI rat model. In addition, LIRI induces NLRP1 inflammasome activation in vivo and in vitro, and KGF-2 inhibits LIRI-induced damage to pulmonary microvascular endothelial cells. Mechanistically, KGF-2 inhibits NLRP1 inflammasome and NF-κB activity. KGF-2 inhibition attenuates LIRI injury-induced damage to endothelial integrity. In conclusion, KGF-2 protects against LIRI by inhibiting inflammation-induced endothelial barrier damage.

Publication types

Retracted Publication